FDA released a safety communication to inform prescribers and patients about a possible increased risk of death in persons with certain kinds of short stature treated with recombinant human growth hormone (also known as somatropin).
FDA released a safety communication to inform prescribers and patients about a possible increased risk of death in persons with certain kinds of short stature treated with recombinant human growth hormone (also known as somatropin). Both FDA and the European Medicines Agency have initiated a safety review of this class of medications.
These ongoing safety reviews and FDA communication are the result of recently released data from the Santé Adulte GH Enfant (SAGhE) study.
Recombinant human growth hormone (marketed in the United States as Genotropin, Humatrope, Norditropin, Nutropin, Nutropin AQ, Omnitrope, Saizen, and Tev-Tropin) is a protein nearly identical to that found naturally in the human body. Whether naturally occurring or recombinant, human growth hormone stimulates tissue growth, height, and metabolism of protein, carbohydrate, lipid, and minerals. It has approved indications for both the adult and pediatric populations.
SAGhE is a long-term epidemiological study designed to assess the long-term mortality of French patients treated with recombinant human growth hormone during childhood between 1985 and 1996. The researchers responsible for conducting this study have recently reported a 30% increased risk of death with recombinant human growth hormone therapy compared to the general population of France (93 observed deaths in the treated group versus 70 expected deaths in the general population), according to a press release. Data suggest the increase in mortality was likely due to excess deaths resulting from bone tumors, cardiovascular, and cerebrovascular events.
Moreover, data from the SAGhE study suggested that the excess death rate seemed greatest in those receiving doses of recombinant growth hormone higher than that normally prescribed for pediatric growth hormone deficiency. Typically doses <50 μg/kg/day are prescribed to treat growth hormone deficiency, except during puberty, when a higher dose regimen is approved for a limited duration of time. Indications other than growth hormone deficiency use doses as high as 69 μg/kg/day.
Despite these uncertainties, FDA is recommending that patients continue their recombinant human growth hormone treatment as prescribed by their healthcare provider. According to Agency officials, "FDA is currently reviewing all available new information on this potential risk and at this time, recommends caution when interpreting the reported results." They continued by emphasizing, "FDA believes the benefits of recombinant growth hormone continue to outweigh the potential risks."
The SAGhE study is funded by the European Commission and conducted by a European consortium of pediatric endocrinologists, epidemiologists, and biostatisticians. The study is still ongoing and further results are expected in the future.
SOURCES
FDA. FDA Drug Safety Communication: Ongoing safety review of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death [12-22-2010]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm237773.htm. Accessed January 6, 2011.
European Medicines Agency. Update on somatropin-containing medicines: Review of somatropin officially started [12-16-10]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/12/news_detail_001167.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true. Accessed January 6, 2011.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.